Reintroduction Of Treatment Target For ESAs For Kidney Failure?
Executive Summary
FDA is considering the reintroduction of a hemoglobin target for erythropoiesis-stimulating agents in the treatment of kidney disease, even though it removed similar language earlier this year from product labeling of the anemia therapies
You may also be interested in...
EPO Dosing Questions Left Unanswered; More Data, More Meetings Needed
Amgen does not currently have enough data to characterize the relationship between targeted hemoglobin levels in patients receiving erythropoiesis-stimulating agents and clinical outcomes in the oncologic setting
Amgen, J&J Barred From Marketing Procrit, Aranesp Chemo-Anemia Benefit
Amgen and Johnson & Johnson are no longer able to promote the impact of their respective erythropoiesis-stimulating agents Aranesp and Procrit on symptoms of anemia in cancer patients, FDA said
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications